

Gc Karakousis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6855576/publications.pdf>

Version: 2024-02-01

220
papers

9,612
citations

81743

39
h-index

45213

90
g-index

223
all docs

223
docs citations

223
times ranked

16416
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , 2018, 560, 382-386.	13.7	1,836
2	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	13.7	1,280
3	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. <i>Nature</i> , 2019, 571, 211-218.	13.7	934
4	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. <i>Immunity</i> , 2020, 52, 825-841.e8.	6.6	497
5	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. <i>Nature Medicine</i> , 2019, 25, 454-461.	15.2	466
6	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
7	Mitotic Rate as a Predictor of Sentinel Lymph Node Positivity in Patients With Thin Melanomas. <i>Annals of Surgical Oncology</i> , 2005, 12, 449-458.	0.7	206
8	Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. <i>Annals of Surgical Oncology</i> , 2020, 27, 1717-1720.	0.7	180
9	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	13.7	146
10	The rise in metastasectomy across cancer types over the past decade. <i>Cancer</i> , 2015, 121, 747-757.	2.0	127
11	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017, 21, 1953-1967.	2.9	117
12	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. <i>Clinical Cancer Research</i> , 2015, 21, 1652-1664.	3.2	106
13	Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. <i>Surgery</i> , 2014, 156, 298-304.	1.0	105
14	Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. <i>Cancer Discovery</i> , 2019, 9, 82-95.	7.7	100
15	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. <i>Cell Reports</i> , 2020, 33, 108571.	2.9	99
16	Predictors of Regional Nodal Disease in Patients With Thin Melanomas. <i>Annals of Surgical Oncology</i> , 2006, 13, 533-541.	0.7	89
17	Outcomes after resection of leiomyosarcomas of the inferior vena cava: A pooled data analysis of 377 cases. <i>Surgical Oncology</i> , 2015, 24, 21-27.	0.8	87
18	Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis. <i>Cancer</i> , 2016, 122, 693-701.	2.0	87

#	ARTICLE	IF	CITATIONS
19	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 162-170.	3.0	81
20	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 1-2.	0.6	75
21	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	2.9	72
22	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	7.7	71
23	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 99-111.	0.6	71
24	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 TÂcells. <i>Cell Reports</i> , 2021, 35, 109120.	2.9	60
25	Neoadjuvant therapy for gastric cancer: current evidence and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 534-43.	0.6	58
26	Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 18-28.	0.6	57
27	Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism. <i>Surgery</i> , 2014, 156, 1394-1403.	1.0	55
28	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <sc>N</sc>ational <sc>C</sc>ancer <sc>D</sc>ata <sc>B</sc>ase. <i>Cancer</i> , 2014, 120, 2855-2865.	2.0	54
29	Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 497-502.e2.	0.6	54
30	Current Staging and Prognostic Factors in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 215-227.	0.6	51
31	Blood Transfusion in Major Abdominal Surgery for Malignant Tumors. <i>JAMA Surgery</i> , 2016, 151, 518.	2.2	51
32	Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. <i>JAMA Dermatology</i> , 2017, 153, 866.	2.0	50
33	Does Surgeon Sex Matter?. <i>Annals of Surgery</i> , 2018, 267, 1069-1076.	2.1	50
34	Human epigenetic and transcriptional TÂcell differentiation atlas for identifying functional TÂcell-specific enhancers. <i>Immunity</i> , 2022, 55, 557-574.e7.	6.6	47
35	Oncogenic BRAF-Mediated Melanoma Cell Invasion. <i>Cell Reports</i> , 2016, 15, 2012-2024.	2.9	46
36	A prognostic model for resectable soft tissue and cutaneous angiosarcoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 557-563.	0.8	45

#	ARTICLE	IF	CITATIONS
37	Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 3803-3810.	0.7	45
38	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. <i>Molecular Cell</i> , 2020, 77, 633-644.e5.	4.5	45
39	Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 643-649.	0.7	42
40	Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk. <i>Annals of Surgical Oncology</i> , 2018, 25, 318-325.	0.7	42
41	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	3.1	42
42	miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 431-441.	1.5	41
43	Prognosis of Patients with Melanoma and Microsatellitosis Undergoing Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 1016-1023.	0.7	37
44	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). <i>Cancer</i> , 2021, 127, 2251-2261.	2.0	37
45	Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database. <i>Cancer</i> , 2017, 123, 967-976.	2.0	35
46	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. <i>Cancer Research</i> , 2016, 76, 2720-2730.	0.4	33
47	Regional Nodal Metastatic Disease Is the Strongest Predictor of Survival in Patients with Thin Vertical Growth Phase Melanomas: A Case for SLN Staging Biopsy in These Patients. <i>Annals of Surgical Oncology</i> , 2007, 14, 1596-1603.	0.7	32
48	Early discharge and readmission after colorectal resection. <i>Journal of Surgical Research</i> , 2014, 190, 579-586.	0.8	32
49	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAF V600E-mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	3.2	32
50	Parathyroidectomy in dialysis patients. <i>Journal of Surgical Research</i> , 2014, 190, 554-558.	0.8	31
51	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600E-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 22-32.	3.2	30
52	The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1096-1098.	0.6	30
53	Adjuvant chemotherapy in resectable synovial sarcoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 550-558.	0.8	29
54	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29

#	ARTICLE	IF	CITATIONS
55	Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. <i>Annals of Surgical Oncology</i> , 2016, 23, 250-256.	0.7	27
56	Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature. <i>Surgical Oncology</i> , 2017, 26, 117-124.	0.8	26
57	The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 245-251.	0.6	26
58	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. <i>Annals of Surgery</i> , 2016, 263, 298-305.	2.1	25
59	Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 848-855.	0.8	25
60	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	1.5	25
61	Implications of Lymph Node Evaluation in the Management of Resectable Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 425-433.	0.7	24
62	Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. <i>Annals of Surgical Oncology</i> , 2017, 24, 952-959.	0.7	23
63	Minimally invasive gastrectomy for gastric adenocarcinoma in the United States: Utilization and short-term oncologic outcomes. <i>Journal of Surgical Oncology</i> , 2015, 112, 616-621.	0.8	22
64	Hernia repair in the presence of ascites. <i>Journal of Surgical Research</i> , 2014, 190, 471-477.	0.8	21
65	Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base. <i>World Neurosurgery</i> , 2018, 112, e812-e822.	0.7	21
66	Melanoma of unknown primary. <i>Journal of Surgical Oncology</i> , 2019, 119, 232-241.	0.8	21
67	Patterns of Metastasis in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 519-529.	0.7	21
68	Age-Related Morbidity and Mortality with Cytoreductive Surgery. <i>Annals of Surgical Oncology</i> , 2015, 22, 898-904.	0.7	20
69	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	1.9	20
70	Local Immune Response Predicts Survival in Patients with Thick (T4) Melanomas. <i>Annals of Surgical Oncology</i> , 2013, 20, 3610-3617.	0.7	19
71	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2016, 23, 2936-2945.	0.7	19
72	Association of Marital Status With T Stage at Presentation and Management of Early-Stage Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 574.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 531-541.	2.3	18
74	Role of adrenal vein sampling in primary aldosteronism: Impact of imaging, localization, and age. <i>Journal of Surgical Oncology</i> , 2016, 113, 532-537.	0.8	18
75	Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?. <i>Cancer</i> , 2018, 124, 125-135.	2.0	18
76	National trends in centralization and perioperative outcomes of complex operations for cancer. <i>Surgery</i> , 2019, 166, 800-811.	1.0	18
77	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	0.7	18
78	Racial Disparities in Initial Presentation of Benign Thyroid Disease for Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 2571-2576.	0.7	17
79	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. <i>Clinical Cancer Research</i> , 2020, 26, 5709-5719.	3.2	17
80	Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 326-336.	0.4	15
81	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 863-872.	0.7	15
82	Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the <sc>US</sc> National Cancer Database. <i>British Journal of Haematology</i> , 2018, 181, 196-204.	1.2	15
83	Transected thin melanoma: Implications for sentinel lymph node staging. <i>Journal of Surgical Oncology</i> , 2018, 117, 567-571.	0.8	15
84	Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00Åmm): A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 433-440.	0.6	15
85	The Landmark Series: Randomized Trials Examining Surgical Margins for Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3-12.	0.7	15
86	Development and Implementation of a Clinical Pathway Approach to Simulation-Based Training for Foregut Surgery. <i>Journal of Surgical Education</i> , 2015, 72, 625-635.	1.2	14
87	Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. <i>JAMA Dermatology</i> , 2016, 152, 836.	2.0	14
88	Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1406-1412.	0.6	14
89	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.2	14
90	Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3469-3475.	0.7	13

#	ARTICLE	IF	CITATIONS
91	Assessment of care pattern and outcome in hemangioblastoma. <i>Scientific Reports</i> , 2018, 8, 11144.	1.6	13
92	Dichotomous and stable gamma delta T-cell number and function in healthy individuals. , 2021, 9, e002274.		13
93	Compliance with sentinel lymph node biopsy guidelines for invasive melanomas treated with Mohs micrographic surgery. <i>Cancer</i> , 2021, 127, 3591-3598.	2.0	13
94	The role of body mass index class in cholecystectomy after acute cholecystitis: An American College of Surgeons National Surgical Quality Improvement Program analysis. <i>Surgery</i> , 2016, 160, 699-707.	1.0	12
95	Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma. <i>Cancer Medicine</i> , 2019, 8, 6295-6304.	1.3	11
96	Multispectral photoacoustic imaging for the detection of subclinical melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 1070-1076.	0.8	11
97	Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41.	0.7	11
98	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2915-2926.	0.7	11
99	Successful Mentor-Mentee Relationship. <i>Journal of Surgical Research</i> , 2020, 247, 332-334.	0.8	11
100	Ninety-day mortality after total gastrectomy for gastric cancer. <i>Surgery</i> , 2021, 170, 603-609.	1.0	11
101	A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells. <i>PLoS ONE</i> , 2015, 10, e0123376.	1.1	11
102	Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. <i>Melanoma Research</i> , 2013, 23, 40-46.	0.6	10
103	Wind, Water, Wound, Walkâ€™Do the Data Deliver the Dictum?. <i>Journal of Surgical Education</i> , 2015, 72, 164-169.	1.2	10
104	Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies. <i>Journal of Surgical Oncology</i> , 2019, 120, 540-549.	0.8	10
105	A Comparison of Cryoablation with Heat-Based Thermal Ablation for Treatment of Clinical T1a Renal Cell Carcinoma: A National Cancer Database Study. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1027-1033.e3.	0.2	10
106	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. <i>Annals of Surgical Oncology</i> , 2019, 26, 4621-4630.	0.7	10
107	Survival Benefit of Adjuvant Radiotherapy in Elderly Patients with WHO Grade III Meningioma. <i>World Neurosurgery</i> , 2019, 131, e303-e311.	0.7	10
108	Lymph Node Evaluation after Neoadjuvant Chemotherapy for Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 1242-1253.	0.7	10

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 5207-5216.	0.7	10
110	Development and validation of a prediction model for patients discharged to post-acute care after colorectal cancer surgery. <i>Surgery</i> , 2017, 161, 1049-1057.	1.0	9
111	Disparities in resection of hepatic metastases in colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 126-134.	0.6	9
112	Comparison of Radiofrequency Ablation and Hepatic Resection for the Treatment of Hepatocellular Carcinoma 2 cm or Less. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1218-1225.e2.	0.2	9
113	Practice Patterns and Prognostic Value of Sentinel Lymph Node Biopsy for Thick Melanoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4651-4662.	0.7	9
114	Predictors of lymph node metastases in patients with mucinous appendiceal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 399-406.	0.8	9
115	Association of the Affordable Care Act's Medicaid expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1628-1635.	0.6	9
116	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.4	9
117	Morbidity and mortality after total splenectomy for lymphoid neoplasms. <i>Journal of Surgical Research</i> , 2016, 205, 155-162.	0.8	8
118	Prophylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative Morbidity. <i>Annals of Surgical Oncology</i> , 2018, 25, 239-245.	0.7	8
119	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. <i>JAMA Oncology</i> , 2018, 4, 126.	3.4	8
120	Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma. <i>Oncologist</i> , 2021, 26, 63-69.	1.9	8
121	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
122	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	0.7	8
123	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
124	Residents'™ Experience in Breast Cancer Care. <i>Journal of Surgical Education</i> , 2015, 72, 1233-1239.	1.2	7
125	Variation in cost of total thyroidectomy across the United States, 2007 to 2008. <i>American Journal of Surgery</i> , 2015, 210, 302-308.	0.9	7
126	Understanding readmissions following operations of the thyroid and parathyroid glands. <i>American Journal of Surgery</i> , 2017, 214, 501-508.	0.9	7

#	ARTICLE	IF	CITATIONS
127	Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database. <i>Leukemia and Lymphoma</i> , 2018, 59, 2105-2112.	0.6	7
128	Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 754-760.	0.6	7
129	Trends in practice patterns and outcomes: A decade of sarcoma care in the United States. <i>Surgical Oncology</i> , 2019, 29, 168-177.	0.8	6
130	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 190-194.	0.7	6
131	Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3234-3235.	0.8	6
132	Impact of COVID-19 Restrictions on Demographics and Outcomes of Patients Undergoing Medically Necessary Non-Emergent Surgeries During the Pandemic. <i>World Journal of Surgery</i> , 2021, 45, 946-954.	0.8	6
133	Obesity is not associated with increased morbidity in patients undergoing cytoreductive surgery with intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2016, 114, 619-624.	0.8	5
134	Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 377-386.	0.7	5
135	Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. <i>British Journal of Haematology</i> , 2018, 181, 752-759.	1.2	5
136	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	0.7	5
137	Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. <i>World Neurosurgery</i> , 2019, 122, e108-e120.	0.7	5
138	Sentinel lymph node positivity and overall survival in immunosuppressed patients with Merkel cell carcinoma: a national cohort study. <i>British Journal of Dermatology</i> , 2020, 183, 569-571.	1.4	5
139	Preoperative Biopsy in Patients with Retroperitoneal Sarcoma: Usage and Outcomes in a National Cohort. <i>Annals of Surgical Oncology</i> , 2021, 28, 6868-6879.	0.7	5
140	New Operative Reporting Standards: Where We Stand Now and Opportunities for Innovation. <i>Annals of Surgical Oncology</i> , 2022, 29, 1797-1804.	0.7	5
141	Surgical Outcomes in Patients With Malignant Small Bowel Obstruction. <i>Annals of Surgery</i> , 2022, 275, e198-e205.	2.1	5
142	Predictive risk-score model for selection of patients with high-risk stage II colon cancer for adjuvant systemic therapy. <i>Surgery</i> , 2022, 171, 1473-1479.	1.0	5
143	Predictors and outcomes of jejunostomy tube placement at the time of pancreatoduodenectomy. <i>Surgery</i> , 2019, 165, 1136-1143.	1.0	4
144	Does multicenter care impact the outcomes of surgical patients with gastrointestinal malignancies requiring complex multimodality therapy?. <i>Journal of Surgical Oncology</i> , 2020, 122, 729-738.	0.8	4

#	ARTICLE	IF	CITATIONS
145	Survival Outcomes Following Lymph Node Biopsy in Thin Melanoma—A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1634-1641.	0.7	4
146	Do microscopic surgical margins matter for primary gastric gastrointestinal stromal tumor?. <i>Surgery</i> , 2021, 169, 419-425.	1.0	4
147	Age and Mitogenicity are Important Predictors of Sentinel Lymph Node Metastasis in T1a Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4777-4779.	0.7	4
148	Optimizing Detection of Lymphatic Invasion in Primary Cutaneous Melanoma With the Use of D2-40 and a Paired Melanocytic Marker. <i>American Journal of Dermatopathology</i> , 2022, 44, 21-27.	0.3	4
149	The impact of the affordable care act on surgeon selection amongst colorectal surgery patients. <i>American Journal of Surgery</i> , 2021, 222, 256-261.	0.9	4
150	Patient characteristics, outcomes, and trends in extremity sarcoma management by surgeon specialty. <i>Surgery</i> , 2021, 170, 1168-1174.	1.0	4
151	Neoadjuvant radiation for cutaneous and soft tissue angiosarcoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 509-515.	0.8	4
152	What is the patient experience of surgical care during the coronavirus disease 2019 (COVID-19) pandemic? A mixed-methods study at a single institution. <i>Surgery</i> , 2021, 170, 550-557.	1.0	4
153	Pathologic Factors Associated with Low Risk of Lymph Node Metastasis in Nonmucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2022, 29, 2334-2343.	0.7	4
154	Conditional survival estimates for merkel cell carcinoma reveal the dynamic nature of prognostication. <i>Journal of Surgical Oncology</i> , 2022, 126, 348-355.	0.8	4
155	Fourteen years of pancreatic surgery for malignancy among ACS-NSQIP centers: Trends in major morbidity and mortality. <i>Surgery</i> , 2022, 172, 708-714.	1.0	4
156	Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma. <i>Oncotarget</i> , 2017, 8, 69038-69046.	0.8	3
157	A case of "tumor-to-tumor" metastasis of cutaneous malignant melanoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 1196-1199.	0.7	3
158	Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 169-172.	0.6	3
159	The effects of the Affordable Care Act on access and outcomes of colon surgery. <i>American Journal of Surgery</i> , 2021, 222, 613-618.	0.9	3
160	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021, 29, 804.	0.7	3
161	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. <i>Oncologist</i> , 2022, 27, 799-808.	1.9	3
162	A risk prediction model for mortality in the moribund general surgical patient. <i>Journal of Critical Care</i> , 2015, 30, 310-314.	1.0	2

#	ARTICLE	IF	CITATIONS
163	Update for ASCO 2015 sarcoma sessions. <i>Surgical Oncology</i> , 2015, 24, 369-370.	0.8	2
164	Lymph node dissection for melanoma: where do we stand?. <i>Melanoma Management</i> , 2017, 4, 49-59.	0.1	2
165	Hospitalization in the Year Preceding Major Oncologic Surgery Increases Risk for Adverse Postoperative Events. <i>Annals of Surgical Oncology</i> , 2017, 24, 3477-3485.	0.7	2
166	Relative survival of patients with central neurocytoma. <i>Journal of Clinical Neuroscience</i> , 2018, 55, 123-124.	0.8	2
167	Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the <sc>US</sc> National Cancer Database. <i>British Journal of Haematology</i> , 2019, 185, 592-595.	1.2	2
168	Association of insurance status with survival in patients with cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1253-1260.	0.6	2
169	Preoperative Transfusion for Anemia in Patients Undergoing Abdominal Surgery for Malignancy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1534-1544.	0.9	2
170	Staging for Melanoma - Toward a New Paradigm?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 873-874.	3.0	2
171	National trends in the presentation of surgically resected appendiceal adenocarcinoma over a decade. <i>Journal of Surgical Oncology</i> , 2021, 123, 606-613.	0.8	2
172	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021, 43, 539-541.	0.3	2
173	Adjuvant therapy for melanoma: how to choose?. <i>Lancet Oncology</i> , The, 2020, 21, 319-320.	5.1	2
174	ASO Author Reflections: Prognostic Significance of Primary Tumor Infiltrating Lymphocytes in the Contemporary Melanoma Era. <i>Annals of Surgical Oncology</i> , 2022, 29, 5217-5218.	0.7	2
175	Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of the American College of Surgeons</i> , 2022, 234, 900-909.	0.2	2
176	The Role of Imaging in Soft Tissue Sarcoma Diagnosis and Management. <i>Surgical Clinics of North America</i> , 2022, 102, 539-550.	0.5	2
177	An Update on Randomized Clinical Trials in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 559-586.	0.6	1
178	Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanomaâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 1136.	3.4	1
179	Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma. <i>Human Pathology</i> , 2019, 88, 78-86.	1.1	1
180	ASO Author Reflections: Surgical Margins for Melanomaâ€”Whatâ€™s Next?. <i>Annals of Surgical Oncology</i> , 2020, 27, 13-14.	0.7	1

#	ARTICLE	IF	CITATIONS
181	Modified Metabolic Syndrome Predicts Worse Outcomes in Obese Patients Undergoing Inguinal Hernia Repair. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1565-1568.	0.9	1
182	Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?. <i>Annals of Surgical Oncology</i> , 2020, 27, 2586-2588.	0.7	1
183	National trends in ventral hernia repairs for patients with intra-abdominal metastases. <i>Surgery</i> , 2020, 168, 509-517.	1.0	1
184	Improving Access to Specialized Centers is Not Enough to Mitigate Socioeconomic Disparities in Complex Oncologic Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 3455-3456.	0.7	1
185	ASO Author Reflections: False Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7004-7005.	0.7	1
186	Local recurrence in patients undergoing wide excision and sentinel lymph node biopsy for cutaneous malignant melanoma: A single-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 247-250.	0.6	1
187	Age and Melanocytic Lesions. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 369-386.	0.6	1
188	Real-world outcomes of pembrolizumab in peritoneal mesothelioma. <i>Journal of Clinical Oncology</i> , 2020, 38, e21094-e21094.	0.8	1
189	ASO Visual Abstract: Lymph Node Evaluation following Neoadjuvant Chemotherapy in Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	1
190	Association Between Underlying Comorbid Conditions and Stage of Presentation in Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	1
191	Simple Prediction Score for Developing Surgical Site Infection after Clean Neck Operation. <i>Surgical Infections</i> , 2022, 23, 400-407.	0.7	1
192	ASO Author Reflections: Survival for Stage III Melanoma—Where Do We Stand in the Current Landscape of Melanoma Therapies?. <i>Annals of Surgical Oncology</i> , 2019, 26, 4631-4632.	0.7	0
193	Let's Not Forget About Regional Therapy for the Treatment of Locally Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2322-2324.	0.7	0
194	Immune checkpoint blockade: an urgent call for biomarkers to help guide treatment. <i>British Journal of Dermatology</i> , 2020, 182, 1085-1086.	1.4	0
195	ASO Author Reflection: Sentinel Lymph Node Biopsy in Thin Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 901-902.	0.7	0
196	Metastatic Melanoma With Features of Desmoplastic Melanoma in a Patient With Primary Cutaneous Superficial Spreading Melanoma With Epithelioid Features. <i>American Journal of Dermatopathology</i> , 2021, 43, 377-380.	0.3	0
197	ASO Author Reflections: Preoperative Biopsy for Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6880-6881.	0.7	0
198	Surgical resection of gastric gastrointestinal stromal tumors (GIST) in octogenarians. <i>American Journal of Surgery</i> , 2021, , .	0.9	0

#	ARTICLE	IF	CITATIONS
199	Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.. Journal of Clinical Oncology, 2021, 39, 9576-9576.	0.8	0
200	Response to a letter to the editor regarding the limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population-level. Journal of the American Academy of Dermatology, 2021, 85, e197-e198.	0.6	0
201	ASO Author Reflections: Number of Examined Lymph Nodes in Gastric Cancer Resection Following Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2021, , 1.	0.7	0
202	ASO Visual Abstract: New Operative Reporting Standards: Where We Stand Now and Opportunities for Innovation. Annals of Surgical Oncology, 2021, 28, 766-767.	0.7	0
203	<i>NRAS</i> and <i>BRAF</i> mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.. Journal of Clinical Oncology, 2013, 31, 9017-9017.	0.8	0
204	Disparities in resection of hepatic metastases in colon cancer.. Journal of Clinical Oncology, 2017, 35, e18062-e18062.	0.8	0
205	Survival after surgery for metastatic small bowel compared to pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2018, 36, 221-221.	0.8	0
206	A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2020, 38, e21093-e21093.	0.8	0
207	Regional Nodal Staging: Clinically Node Negative. , 2021, , 125-147.		0
208	The impact of hospital volume on racial disparities in resected rectal cancer. Journal of Surgical Oncology, 2022, 125, 465-474.	0.8	0
209	Implications of Lymph Node Evaluation in Crohn's Patients with Small-Bowel Adenocarcinoma. Journal of Gastrointestinal Surgery, 2022, 26, 1311-1313.	0.9	0
210	Melanoma Surgery in the Emerging Era of Effective Neoadjuvant Therapy. Annals of Surgical Oncology, 2022, 29, 760-761.	0.7	0
211	ASO Author Reflections: Risk Factors for Lymph Node Metastasis in Non-mucinous Adenocarcinoma of the Appendix. Annals of Surgical Oncology, 2022, 29, 2344-2345.	0.7	0
212	Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab. Annals of Surgical Oncology, 2022, , 1.	0.7	0
213	ASO Visual Abstract: Pathologic Factors Associated With Low Risk of Lymph Node Metastasis in Non-Mucinous Adenocarcinoma of the Appendix. Annals of Surgical Oncology, 2022, 29, 2346.	0.7	0
214	Prognostic Biomarkers in Melanoma: The Legacy of a Surgeon Scientist Who Followed the Data. Annals of Surgical Oncology, 2022, , 1.	0.7	0
215	Dedication to late Dale Han, MD. Clinical and Experimental Metastasis, 2022, 39, 257-257.	1.7	0
216	ASO Visual Abstract: Prognostic Significance of Primary-Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Annals of Surgical Oncology, 2022, , 1.	0.7	0

#	ARTICLE	IF	CITATIONS
217	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , .	0.6	0
218	Postsplenectomy morbidity and mortality in patients with immune thrombocytopenic purpura: A national cohort study. Journal of Surgical Oncology, 0, , .	0.8	0
219	Clinical activity of pembrolizumab monotherapy in diffuse malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2022, 40, 8557-8557.	0.8	0
220	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.. Journal of Clinical Oncology, 2022, 40, 9569-9569.	0.8	0